Fibronectin targeted IL-12 Development Service
Creative Biolabs' service is designed to take the most challenging aspects of immunocytokine (IC) development—specifically interleukin-12 (IL-12) stability and toxicity management—and transform them into a reliable therapeutic strategy. We focus on providing solutions grounded in the clinically validated success of ED-B targeting. This expertise allows us to engineer next-generation IL-12 fusion proteins that safely anchor the potent cytokine payload to the tumor site. This maximizes local IL-12 concentration and therapeutic efficacy while effectively minimizing systemic risk, delivering IC candidates ready for IND-enabling studies.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
The IL-12 Dilemma: Unlocking Potency While Overcoming Systemic Toxicity
IL-12 is a fundamentally important heterodimeric, pleiotropic cytokine and master regulator that links innate and adaptive immunity, promising remarkable anti-tumor efficacy. Its power stems from driving the T helper type 1 (Th1) Immune Shift, activating cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and critically reprogramming immunosuppressive TAMs/MDSCs, and inducing IFN-γ. However, early systemic delivery resulted in severe, dose-limiting toxicities, necessitating the modern approach. Our next-generation immunocytokine platform's core mission is to maximize the local concentration of bioactive IL-12 at the tumor site to drive this efficacy while drastically minimizing its systemic residence time and associated toxicity.
Key Deliverables and Problem-Solving Capabilities
Maximize Tumor Retention (Depot Effect)
We engineer ICs for superior binding to the oncofetal ED-B fibronectin, ensuring high-concentration IL-12 is retained at the tumor site for prolonged, sustained immune activation.
Superior Therapeutic Index
By focusing on IC delivery, we enable the establishment of a safe maximum tolerated dose (MTD) (e.g., 15 µg/kg/week) that is dramatically higher than what is achievable with non-targeted, systemic IL-12.
Guaranteed Stoichiometric Stability
Our proprietary fusion techniques ensure the reliable and stable assembly of the biologically active p70 IL-12 heterodimer onto the full-IgG scaffold, a key challenge for this cytokine.
Mitigation of Immunogenicity Risk
We provide detailed analysis to confirm that any anti-drug antibodies (ADA) that develop do not neutralize the biological function of the IC, securing its therapeutic viability.
Discover How We Can Help - Request a Consultation
Workflow
The following workflow illustrates the high-precision, multi-stage process we employ, which is suitable for visualization as a comprehensive flowchart.
Why Choose Us?
We don't just offer theoretical designs; our strategy is validated by successful development (e.g., AS1409) to address IL-12's primary historical roadblock: toxicity. Our unique approach leverages the inherent specificity of the ED-B target, achieving a proven therapeutic index with an MTD—a massive safety improvement over legacy therapies. The full IgG format ensures extended pharmacokinetics via FcRn binding, delivering a ~22-hour serum half-life critical for sufficient tumor accumulation. Our team provides expert risk mitigation against structural instability and immunogenicity.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q: How does your fibronectin-targeted IC compare to traditional systemic IL-12?
A: Our targeted approach drastically improves the therapeutic index. Systemic IL-12 had severe toxicity at low doses, while ICs, developed using this strategy, have an established MTD and show genuine anti-tumor efficacy with manageable toxicity because the cytokine is concentrated at the tumor site.
Q: Which tumor types are most suitable for ED-B targeting?
A: ED-B fibronectin is massively up-regulated in the stroma of nearly all aggressive solid tumors, including melanoma, prostate, colon, and gliomas. The target is highly versatile, making this strategy applicable to a very broad range of difficult-to-treat malignancies.
Q: What steps do you take to manage the risk of immunogenicity (ADA)?
A: We minimize immunogenicity through humanization of the targeting antibody and rigorous in vitro and in vivo testing. Critically, we confirm that even if ADA is formed, they do not neutralize the biological activity, ensuring the therapeutic payload remains functional.
Customer Review
-
Optimized PK/Half-life
Using Creative Biolabs' service in our research has significantly improved the serum β-half-life of our conjugate, moving us from a single-chain fragment to a stable, full-IgG format that ensures better tumor exposure. - Dr. M*n
-
Reprogramming TME
The detailed pharmacodynamic (PD) data provided by Creative Biolabs clearly demonstrated the IC's superior ability to reprogram the tumor microenvironment, specifically showing a strong reduction in immunosuppressive TAMs. - P. N*s
Related Services
To further support your targeted immunotherapy project, Creative Biolabs offers several complementary services:
Antibody Humanization Service
Creative Biolabs offers customized antibody humanization services using various methods to modify non-human antibodies, thus reducing immunogenicity for success as therapeutic agents.
Learn More →
Variable Region Sequencing and Cloning
Creative Biolabs offers antibody variable region (VH and VL) sequencing and cloning services from hybridomas/B cells to enable antibody humanization, engineering, and recombinant antibody production.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs is your specialized partner for high-precision, low-risk immunocytokine development. We translate the complex science of TME targeting and cytokine engineering into a clinically validated, accelerated development pathway, ensuring your therapeutic asset achieves maximum potency and a safe therapeutic index.
Reach out to our scientific team to discuss your specific IL-12 project requirements, review our detailed data package, and begin designing your custom development plan.
